Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression

AYDEMİR, Ömer; DANACI, Ayşen Esen; DEVECİ, Altuner; CERRAHOĞLU, AYŞE BEYHAN LALE; TAŞKIN, E. Oryal; TANELİ, FATMA; SELÇUKİ, Deniz

Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression

E. Oryal TAŞKIN, (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

Ömer AYDEMİR, (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

Altuner DEVECİ, (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

Fatma TANELİ, (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

Deniz SELÇUKİ, (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

AYŞE BEYHAN LALE CERRAHOĞLU, (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

Ayşen Esen DANACI (Celal Bayar Üniversitesi, Tıp Fakültesi, Manisa, Türkiye)

Klinik Psikofarmakoloji Bülteni

3 1

Yıl: 2008 Cilt: 18 Sayı: 4 Sayfa Aralığı: 259 - 265 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression

Öz:

Amaç: Bu çalışmada, ağrılı semdromların ortaya çıkmasında stresin rolünün araştırılması amacıyla migren ve fibromiyalji tanılı hastaların serum Beyin-türevli Nörotrofik Faktör (BDNF) düzeyleri depresif hastaların ve sağlıklı kontrollerin düzeyleri ile karşılaştırılmıştır. Yöntem: Önceden herhangi bir psikiyatrik tanısı olmayan ve antidepresan tedavi kullanmamış olan 27 migren tanılı hasta ve 19 fibromiyalji tanılı hasta çalışmaya alınmıştır. Depresyon grubuna ise en az sekiz haftadır antidepresan tedavi kullanmayan major depresif bozukluk tanılı 24 hasta dahil edilmiştir. Bu grupta da depresyona eşlik eden başka bir birinci eksen tanısı olan hasta yoktur. Herhangi bir psikiyatrik tanısı bulunmayan ve psikiyatrik tedavi kullanmamış olan 26 sağlıklı denek kontrol grubunu oluşturmuştur. Tüm gruplardaki deneklerin depresyon ve diğer eksen I tanılarının değerlendirlmesi için DSM- IV için Yapılandırılmış Klinik Görüşme Kılavuzu (SCID-I) kullanılarak tanısal görüşme yapılmıştır. Deneklerin depresyon şiddetinin belirlenmesi için Hamilton Depresyon Derecelendirme Ölçeği (HAM-D) kullanılmıştır. Migren tanısı için Uluslararası Başağrısı Birliği’nin belirlediği ölçütlere göre konmuştur. Fibromiyaljı tanısı için ise American College of Rheumatology ölçütleri kullanılmıştır. Fibromiyalji ve migren hastalarında ağrı şiddeti visual analogue scale (VAS) ile değerlendirilmiştir. BDNF ölçümü için serum örneği -70°C derecede saklanmış ve kit ile beraber verilen Block ve Sample solüsyon ile dilüe edildikten sonra ELISA Kit (Promega; Madison, WI, ABD) ile çalışılmıştır. Verilerin değerlendirilmesinde, serum BDNF değerlerinin ortalamalarının kıyaslanması için Kruskal Wallis testi uygulanmıştır. Serum BDNF düzeylerinin yaşla ilişkisinin değerlendirilmesinde Spearman sıralı korelasyon testi, cinsiyetle ilişkisinin değerlendirilmesinde Bonferroni düzeltmeli Mann Whitney U testi kullanılmıştır. Serum BDNF düzeylerinin HAM-D ve VAS puanları arasındaki ilişkinin test edilmesi için Spearman sıralı korelasyon testi uygulanmıştır. Bulgular: Depresyon grubunun serum BDNF düzeyleri (21.2±11.3 ng/ml), migren grubunun (32.2±10.1 ng/ml), fibromiyalji grubunun (30.7±8.9 ng/ml) ve kontrol grubunun (31.4±8.8 ng/ml) düzeylerinden istatistiksel olarak anlamlı düzeyde düşük bulunmuştur (p<0.0001). Migren, fibromiyalji ve kontrol grupları arasında serum BDNF düzeyleri açısından istatistiksel olarak anlamlı bir farklılık bulunmamıştır. Serum BDNF düzeyleri ile, yaş ve cinsiyet arasında istatistiksel olarak anlamlı bir ilişki yoktur. Ağrılı sendromlarda HAM-D ve VAS puanları ile serum BDNF düzeyleri arasında istatistiksel olarak anlamlı bir korelasyon olmadığı görülmüştür (sırası ile r= 0.085; p= 0.579 ve r= 0.191; p= 0.204). benzer şekilde depresyon grubunda da serum BDNF düzeyleri ile HAM-D puanları arasında anlamlı bir ilişki yoktur (r= 0.122; p= 0.579). Sonuçlar: Ağrılı sendromlar stres ile ilişkilendirilse bile, bu çalışmada, stresin bir belirteci olan serum BDNF düzeyi bu görüşü desteklememiştir. Bu durumun nedeni fibromiyalji veya migren gibi ağrılı sendromlarda serum BDNF düzeylerinin periferik trombosit işlevlerindeki değişimlerden etkilenmesi olabilir. Öte yandan belli bir düzeyde kalan kronik stres durumlarından serum BDNF düzeylerinin etkilenmiyor olması da bu durumda rol oynamış olabilir.

Anahtar Kelime: Ağrı Psikiyatrik durum derecelendirme ölçekleri Beyin-kökenli nörotropfik faktör Karşılaştırmalı çalışma Migren bozuklukları Fibromiyalji Depresif bozukluk, majör

Konular: Farmakoloji ve Eczacılık

Ağrılı sendromlarda serum beyin-türevli nörotrofik faktör düzeyleri: Major depresyon ile kontrollü bir çalışma

Öz:

Objective: In this study, it is aimed to compare the level of Brain-Derived Neurotrophic Factor (BDNF) of patients with migraine and fibromyalgia to that of depressive patients and healthy subjects in order to answer the question whether stress is related to pain syndromes. Methods: In the migraine group 27 patients and in the fibromyalgia group 19 patients without any previous antidepressant treatment and psychiatric diagnosis were included. In the depression group, 24 patients with at least eight weeks of antidepressant-free period were invited to the study. In the depression group no co-morbid diagnosis in the first axis was made. Twenty-six subjects without any previous psychiatric diagnosis and psychiatric treatment consisted the control group. For making diagnosis of depression and other first axis disorders Structured Clinical Interview for DSM- IV (SCID-I) was used in all study groups. For the assessment of the severity of depression Hamilton Depression Rating Scale (HAM-D) was applied. The diagnosis of migraine was made according to the criteria of International Headache Society. For the diagnosis of the fibromyalgia the criteria of American College of Rheumatology was used. The severity of pain was assessed with visual analogue scale (VAS) in the migraine and fibromyalgia groups. Serum BDNF was kept at -70°C before testing, and assayed with an ELISA Kit (Promega; Madison, WI, USA), after dilution with the Block and Sample solution provided with the kit. The data were subjected to Kruskal Wallis Test in the comparison of serum BDNF levels. Results: The serum BDNF level of the depression group (21.2±11.3 ng/ml) was statistically lower (p<0.0001) than the level of the migraine group (32.2±10.1 ng/ml), fibromyalgia group (30.7±8.9 ng/ml) and the control group (31.4±8.8 ng/ml). The level of BDNF was not significantly different in the migraine, fibromyalgia and control groups. There was no significant correlation between serum BDNF levels, and age and gender. In pain syndromes there was no signification correlation between serum BDNF levels, and mean scores of HAM-D and VAS (r= 0.085; p= 0.579 and r= 0.191; p= 0.204 respectively). Similarly there was no significant correlation between serum BDNF levels and HAM-D scores in the depression group (r=0.122; p= 0.579). Conclusions: Even though the pain syndromes were suggested to be associated with stress, in this present work, serum BDNF level as one of the markers of stress does not support this hypothesis. This might be related to the factor that in pain syndromes such as fibromyalgia or migraine, serum BDNF level may be affected by the alteration in peripheral platelet functions. Furthermore in a limited chronic stress serum BDNF levels tend to be not affected and this may play a significant role in our results.

Anahtar Kelime: Brain-Derived Neurotrophic Factor Comparative Study Migraine Disorders Fibromyalgia Depressive Disorder, Major Pain Psychiatric Status Rating Scales

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Popoli M, Gennarelli M, Racagni G. Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord 2002; 4:166-182
2. McAllister AK. Neurotrophins and neuronal differentation in the central nervous system. Cell Mol Life Sci 2001; 58:1054-1060
3. Poo MM. Neurotrophins as synaptic modulators. Neurosci 2001; 2:24-32
4. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27:589-594
5. D’Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4;183-194
6. Angelucci F, Mathe AA, Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 2004; 146:151-165
7. Lewin Gr, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996; 19:289-317
8. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in depressed patients. Psychiatry Res 2002; 109:143-148
9. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:261-265
10. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15:1768-1777
11. Scaccianoce S, Lombardo K, Angelucci I. Nerve growth factor brain concentration and stress: changes depend on type of stressor and age. Int Dev Neurosci 2000; 18:469-479
12. Alfonso J, Pollevick GD, Vander Hart MG, Flugge G, Fucks E, Frasch AC. Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. Eur J Neurosci 2004; 19:659-666
13. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59:1116-1127
14. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci1999;22:105-122
15. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorderds. Neuromolecular Med 2004; 5:11-25
16. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 1999; 89:157-1656
17. Hudson JI, Pope HG. Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology. Am J Psychiatry 1990; 147:552-564
18. Hudson JI, Mangweth B, Pope HG, Jr De Col C, Hausmann A, Gutweniger S, Laird NM, Biebl W, Tsuang MT. Family study of affective spectrum disorder. Arc Gen Psychiatry 2003; 60:170-177
19. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003; 60:39-47
20. Laske C, Stransky E, Eschweiler GW, Klein R, Wittorf A, Leyhe T, Richartz E, Köhler N, Bartels M, Buchkremer G, Schott K. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007;41:600-605
21. Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res 2006; 55:1-10
22. Duric V, McCarson KE. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 2005; 133:999-1006
23. Xu HW, Li XC, Li HD, Ruan HZ, Liu ZZ. Effects of corticotropin on pain behaviour and BDNF, CRF levels in frontal cortex of rats suffering from chronic pain. Acta Pharmacol Sin 2000; 21:600-604
24. First MB, Spitzer RL, Gibbon M, Williams JBWl. Structured Clinical Interview for DSM- IV Clinical Version (SCID-I/CV). American Psychiatric Press, Washington DC. 1997
25. Ozkurkcugil A, Aydemir O, Yildiz, M., Esen A, Koroglu E. Structured Clinical Interview for DSM-IV (SCID-IV), Turkish Version. ‹laç ve Tedavi Dergisi 1999; 12:233-236 [Turkish]
26. Williams BW. A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psychiatr, 1978; 45: 742-747
27. Aydemir O, Deveci A, Icelli I. Reliability and validity of the Turkish version of the structured interview guide for Hamilton Depression Rating Scale Seasonal Affective Disorder. Psychiatry in Turkey 2006;8:18-21
28. Wolf F, Potter J. Fibromyalgia and work disability. In: Goldenberg DL, eds. Controversies in Fibromyalgia and Related Conditions. Philadelphia: W. B. Saunders Co., 1996: 369
29. Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis. 1979; 38:560.
30. Headache Classification Subcommitte of the HIS. The international classification of headache disorders, 2nd Edition. Cephalalgia 2004; 24(supp 1):1-160
31. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P et al. The American College of Rheumatology 1990 Criteria for the Classificiation of Fibromyalgia. Report of the Multicenter Criteria Committe. Arthiritis Rheum 1990; 33:160-172
32. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38:19-28
33. Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am 1989; 15:1-18
34. Wingenfeld K, Wagner D, Schmidt I, Meinlschmidt G, Hellhammer DH, Heim C. The low dose dexamethasone test in fibromyalgia. Journal of Psychosomatic Research 2007; 62:85-91
35. Crofford KL, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37:1583-1592
36. Joseph R, Welch KM, D’Andrea G. Serotonergic hypofunction in migraine: synthesis of evidence based on platelet dense body dysfunction. Cephalalgia1989;9:293-299
37. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: is the association specific to migraine? Neurology 2000; 54:308-313
38. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000; 55:629-635
39. Stewart WF, Linet MS, Celentano DD. Migraine headaches and panic attacks. Psychosom Med 1989; 51:559-569
40. Zeller JA, Frahm K, Baron R, Stingele R, Deuschl G. Plateletleukocyte interaction and platelet activation in migraine: a link to ischemic stroke? J Neurol Neurosurg Psychiatry 2004; 75:984-98.
41. Blandini F, Rinaldi L, Tassorelli C, Sances G, Motta M, Samuele A, Fancellu R, Nappi G, Leon A. Peripheral levels of BDNF and NGF in primary headaches. Cephalalgia 2005; 26:136-142
42. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328:261-264
43. Kuroda Y, McEwen BS. Effect of chronic restraint stress and tianeptine on growth factors, growth-associated protein-43 and microtubule-associated protein 2 mRNA expression in the rat hippocampus. Brain Res Mol Brain Res 1998; 59:35-39
44. Aydemir O, Deveci A, Taskin EO, Taneli F, Esen-Danaci A. Serum brain-derived neurotrophic factor level in dysthymia: A comparative study with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1023-1026

APA	TAŞKIN E, AYDEMİR Ö, DEVECİ A, TANELİ F, SELÇUKİ D, CERRAHOĞLU A, DANACI A (2008). Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. , 259 - 265.
Chicago	TAŞKIN E. Oryal,AYDEMİR Ömer,DEVECİ Altuner,TANELİ FATMA,SELÇUKİ Deniz,CERRAHOĞLU AYŞE BEYHAN LALE,DANACI Ayşen Esen Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. (2008): 259 - 265.
MLA	TAŞKIN E. Oryal,AYDEMİR Ömer,DEVECİ Altuner,TANELİ FATMA,SELÇUKİ Deniz,CERRAHOĞLU AYŞE BEYHAN LALE,DANACI Ayşen Esen Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. , 2008, ss.259 - 265.
AMA	TAŞKIN E,AYDEMİR Ö,DEVECİ A,TANELİ F,SELÇUKİ D,CERRAHOĞLU A,DANACI A Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. . 2008; 259 - 265.
Vancouver	TAŞKIN E,AYDEMİR Ö,DEVECİ A,TANELİ F,SELÇUKİ D,CERRAHOĞLU A,DANACI A Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. . 2008; 259 - 265.
IEEE	TAŞKIN E,AYDEMİR Ö,DEVECİ A,TANELİ F,SELÇUKİ D,CERRAHOĞLU A,DANACI A "Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression." , ss.259 - 265, 2008.
ISNAD	TAŞKIN, E. Oryal vd. "Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression". (2008), 259-265.

APA	TAŞKIN E, AYDEMİR Ö, DEVECİ A, TANELİ F, SELÇUKİ D, CERRAHOĞLU A, DANACI A (2008). Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. Klinik Psikofarmakoloji Bülteni, 18(4), 259 - 265.
Chicago	TAŞKIN E. Oryal,AYDEMİR Ömer,DEVECİ Altuner,TANELİ FATMA,SELÇUKİ Deniz,CERRAHOĞLU AYŞE BEYHAN LALE,DANACI Ayşen Esen Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. Klinik Psikofarmakoloji Bülteni 18, no.4 (2008): 259 - 265.
MLA	TAŞKIN E. Oryal,AYDEMİR Ömer,DEVECİ Altuner,TANELİ FATMA,SELÇUKİ Deniz,CERRAHOĞLU AYŞE BEYHAN LALE,DANACI Ayşen Esen Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. Klinik Psikofarmakoloji Bülteni, vol.18, no.4, 2008, ss.259 - 265.
AMA	TAŞKIN E,AYDEMİR Ö,DEVECİ A,TANELİ F,SELÇUKİ D,CERRAHOĞLU A,DANACI A Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. Klinik Psikofarmakoloji Bülteni. 2008; 18(4): 259 - 265.
Vancouver	TAŞKIN E,AYDEMİR Ö,DEVECİ A,TANELİ F,SELÇUKİ D,CERRAHOĞLU A,DANACI A Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression. Klinik Psikofarmakoloji Bülteni. 2008; 18(4): 259 - 265.
IEEE	TAŞKIN E,AYDEMİR Ö,DEVECİ A,TANELİ F,SELÇUKİ D,CERRAHOĞLU A,DANACI A "Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression." Klinik Psikofarmakoloji Bülteni, 18, ss.259 - 265, 2008.
ISNAD	TAŞKIN, E. Oryal vd. "Serum brain-derived neurotrophic factor levels in pain syndromes: A comparative study with major depression". Klinik Psikofarmakoloji Bülteni 18/4 (2008), 259-265.